Table 3. Univariate associations with OS and DFS.
| Association | OS | DFS | |||
|---|---|---|---|---|---|
| HR (95% CI) | P valuea | HR (95% CI) | P valuea | ||
| Age, years | 0.03 | 0.048 | |||
| <60 | 0.5 (0.2–1.0) | 0.5 (0.2–1.0) | |||
| ≥60 | 1.0 (Reference) | 1.0 (Reference) | |||
| Type of treatment | <0.001 | <0.001 | |||
| Surgical resection/aCRT | 0.3 (0.1–0.6) | 0.3 (0.2–0.7) | |||
| dCRT | 1.0 (Reference) | 1.0 (Reference) | |||
| nCRT/OLT | 0.1 (0.1–0.3) | 0.2 (0.1–0.4) | |||
| Ulcerative colitis | 0.17 | 0.30 | |||
| Yes | 0.6 (0.3–1.3) | 0.7 (0.3–1.5) | |||
| No | 1.0 (Reference) | 1.0 (Reference) | |||
| PSC | 0.13 | 0.28 | |||
| Yes | 0.6 (0.3–1.2) | 0.7 (0.3–1.4) | |||
| No | 1.0 (Reference) | 1.0 (Reference) | |||
| Sex | 0.26 | 0.28 | |||
| Female | 1.5 (0.8–3.0) | 1.5 (0.7–2.9) | |||
| Male | 1.0 (Reference) | 1.0 (Reference) | |||
| ECOG performance status | 0.10 | 0.10 | |||
| 0 | 1.0 (Reference) | 1.0 (Reference) | |||
| 1 | 1.4 (0.7–2.8) | 1.3 (0.7–2.6) | |||
| 2 | 4.0 (0.9–17.4) | 4.3 (1.4–13.1) | |||
| Location | 0.32 | 0.16 | |||
| Hilar | 1.0 (Reference) | 0.62 (0.3–1.3) | |||
| Distal | 0.7 (0.3–1.4) | 1.0 (Reference) | |||
| Clinical tumor stage | 0.40 | 0.10 | |||
| T0-T2 | 1.0 (Reference) | 1.0 (Reference) | |||
| T3/T4 | 1.3 (0.7–2.5) | 1.7 (0.4–3.1) | |||
| Clinical node stage | 0.02 | 0.03 | |||
| N0 | 1.0 (Reference) | 1.0 (Reference) | |||
| N1/N2 | 2.3 (1.2–4.5) | 2.1 (1.1–4.1) | |||
| Stent | 0.85 | 0.70 | |||
| Yes | 1.0 (Reference) | 1.0 (Reference) | |||
| No | 1.0 (0.4–2.2) | 0.8 (0.4–1.8) | |||
| Tumor size | <0.001 | <0.001 | |||
| ≤3 | 1.0 (Reference) | 1.0 (Reference) | |||
| >3 | 3.3 (1.7–6.4) | 3.8 (2.0–7.4) | |||
a, Type 3 likelihood-ratio P value. aCRT, adjuvant chemoradiotherapy; dCRT, definitive chemoradiotherapy; DFS, disease-free survival; ECOG, Eastern Cooperative Oncology Group; nCRT/OLT, neoadjuvant chemoradiotherapy followed by orthotopic liver transplantation; OS, overall survival; PSC, primary sclerosing cholangitis.